FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.	C. 20549
----------------	----------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Dorton Katina (Last) (First) (Middle) C/O TSCAN THERAPEUTICS, INC. 830 WINTER STREET (Street) WALTHAM MA 02451 (City) (State) (Zip)					3. D	2. Issuer Name and Ticker or Trading Symbol TScan Therapeutics, Inc. [TCRX] 3. Date of Earliest Transaction (Month/Day/Year) 06/01/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)							(C	X Dire Offic belo	ctor er (give title w) r Joint/Grou	Or 10% Owner C (give title Other (specify below) Joint/Group Filing (Check Applicable filed by One Reporting Person filed by More than One Reporting		
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ection	ction 2A. Deemed Execution Date,			3. Transac Code (II 8)	ction	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)			r 5. Amount of		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
(e.g., pu 1. Title of				u ts , (l. Transa Code (l	calls, warrants, c			ired, Disposed of, options, convertil b. Date Exercisable and Expiration Date Month/Day/Year)			, or Beneficial ble securities 7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)			f 9. Numbe	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
Stock Option (Right to	\$3.17	06/01/2022		C	Code	v	(A) 9,146		Date Exercisable	e D	expiration ate	Title Voting Common	Amount or Number of Shares	\$0.00	9,146	5	D	
Buy)	f D											Stock						

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.

Remarks:

/s/ Katina Dorton

06/03/2022

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.